@Article{096504017X14992942781895,
AUTHOR = {Dina Polosukhina, Harold D. Love, Harold L. Moses, Ethan Lee, Roy Zent, Peter E. Clark},
TITLE = {Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits  Murine and Human Models of Wilms Tumor},
JOURNAL = {Oncology Research},
VOLUME = {25},
YEAR = {2017},
NUMBER = {9},
PAGES = {1653--1664},
URL = {http://www.techscience.com/or/v25n9/56950},
ISSN = {1555-3906},
ABSTRACT = {Wilms tumor (WT) is the most common renal malignancy in children and the fourth most common pediatric 
solid malignancy in the US. Although the mechanisms underlying the WT biology are complex, these tumors 
most often demonstrate activation of the canonical Wnt/β-catenin pathway. We and others have shown that 
constitutive activation of β-catenin restricted to the renal epithelium is sufficient to induce primitive renal 
epithelial tumors, which resemble human WT. Here we demonstrate that pharmacologic inhibition of β-catenin 
gene transcription with pyrvinium inhibits tumor growth and metastatic progression in a murine model of WT. 
Cellular invasion is significantly inhibited in both murine WT-like and human WT cells and is accompanied by 
downregulation of the oncogenes Myc and Birc5 (survivin). Our studies provide proof of the concept that the 
canonical Wnt/β-catenin pathway may be a novel therapeutic target in the management of WT.},
DOI = {10.3727/096504017X14992942781895}
}